Cargando…

Fructose: a modulator of intestinal barrier function and hepatic health?

PURPOSE: Consumption of fructose has repeatedly been discussed to be a key factor in the development of health disturbances such as hypertension, diabetes type 2, and non-alcoholic fatty liver disease. Despite intense research efforts, the question if and how high dietary fructose intake interferes...

Descripción completa

Detalles Bibliográficos
Autores principales: Staltner, Raphaela, Burger, Katharina, Baumann, Anja, Bergheim, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611622/
https://www.ncbi.nlm.nih.gov/pubmed/37596353
http://dx.doi.org/10.1007/s00394-023-03232-7
_version_ 1785128530971983872
author Staltner, Raphaela
Burger, Katharina
Baumann, Anja
Bergheim, Ina
author_facet Staltner, Raphaela
Burger, Katharina
Baumann, Anja
Bergheim, Ina
author_sort Staltner, Raphaela
collection PubMed
description PURPOSE: Consumption of fructose has repeatedly been discussed to be a key factor in the development of health disturbances such as hypertension, diabetes type 2, and non-alcoholic fatty liver disease. Despite intense research efforts, the question if and how high dietary fructose intake interferes with human health has not yet been fully answered. RESULTS: Studies suggest that besides its insulin-independent metabolism dietary fructose may also impact intestinal homeostasis and barrier function. Indeed, it has been suggested by the results of human and animal as well as in vitro studies that fructose enriched diets may alter intestinal microbiota composition. Furthermore, studies have also shown that both acute and chronic intake of fructose may lead to an increased formation of nitric oxide and a loss of tight junction proteins in small intestinal tissue. These alterations have been related to an increased translocation of pathogen-associated molecular patterns (PAMPs) like bacterial endotoxin and an induction of dependent signaling cascades in the liver but also other tissues. CONCLUSION: In the present narrative review, results of studies assessing the effects of fructose on intestinal barrier function and their impact on the development of health disturbances with a particular focus on the liver are summarized and discussed.
format Online
Article
Text
id pubmed-10611622
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106116222023-10-29 Fructose: a modulator of intestinal barrier function and hepatic health? Staltner, Raphaela Burger, Katharina Baumann, Anja Bergheim, Ina Eur J Nutr Review PURPOSE: Consumption of fructose has repeatedly been discussed to be a key factor in the development of health disturbances such as hypertension, diabetes type 2, and non-alcoholic fatty liver disease. Despite intense research efforts, the question if and how high dietary fructose intake interferes with human health has not yet been fully answered. RESULTS: Studies suggest that besides its insulin-independent metabolism dietary fructose may also impact intestinal homeostasis and barrier function. Indeed, it has been suggested by the results of human and animal as well as in vitro studies that fructose enriched diets may alter intestinal microbiota composition. Furthermore, studies have also shown that both acute and chronic intake of fructose may lead to an increased formation of nitric oxide and a loss of tight junction proteins in small intestinal tissue. These alterations have been related to an increased translocation of pathogen-associated molecular patterns (PAMPs) like bacterial endotoxin and an induction of dependent signaling cascades in the liver but also other tissues. CONCLUSION: In the present narrative review, results of studies assessing the effects of fructose on intestinal barrier function and their impact on the development of health disturbances with a particular focus on the liver are summarized and discussed. Springer Berlin Heidelberg 2023-08-18 2023 /pmc/articles/PMC10611622/ /pubmed/37596353 http://dx.doi.org/10.1007/s00394-023-03232-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Staltner, Raphaela
Burger, Katharina
Baumann, Anja
Bergheim, Ina
Fructose: a modulator of intestinal barrier function and hepatic health?
title Fructose: a modulator of intestinal barrier function and hepatic health?
title_full Fructose: a modulator of intestinal barrier function and hepatic health?
title_fullStr Fructose: a modulator of intestinal barrier function and hepatic health?
title_full_unstemmed Fructose: a modulator of intestinal barrier function and hepatic health?
title_short Fructose: a modulator of intestinal barrier function and hepatic health?
title_sort fructose: a modulator of intestinal barrier function and hepatic health?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611622/
https://www.ncbi.nlm.nih.gov/pubmed/37596353
http://dx.doi.org/10.1007/s00394-023-03232-7
work_keys_str_mv AT staltnerraphaela fructoseamodulatorofintestinalbarrierfunctionandhepatichealth
AT burgerkatharina fructoseamodulatorofintestinalbarrierfunctionandhepatichealth
AT baumannanja fructoseamodulatorofintestinalbarrierfunctionandhepatichealth
AT bergheimina fructoseamodulatorofintestinalbarrierfunctionandhepatichealth